NextCure, Inc.
NXTCNasdaq
$5.99
↓ -2.9%Jul 17 close · end-of-day
Price
1Y↑ +24.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$31.4M
Enterprise Value
$16.2M
P/E
—
P/S
—
P/B
1.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$54.7M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-204.6%
ROIC
-383.7%
Debt / Equity
—
Net Cash
$15.2M
Return 1Y
+16.8%
Company profile
NextCure, Inc. engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. NC410, NC762, NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells.
- CEO
- Michael S. Richman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Maryland
- Website
- nextcure.com
Earnings
NXTC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.87↓ -60.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $22.4M | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$41.2M | -$70.8M | -$75.9M | -$67.6M | -$59.7M | -$57.6M |
| Net income | -$36.6M | -$69.4M | -$74.7M | -$62.7M | -$55.7M | -$55.8M |
| Diluted EPS | -$1.33 | -$2.51 | -$2.69 | -$2.25 | -$23.88 | -$19.65 |
| Operating cash flow | -$45.0M | -$57.3M | -$53.9M | -$53.0M | -$40.8M | -$49.6M |
| Free cash flow | -$52.1M | -$59.6M | -$56.0M | -$53.8M | -$41.3M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -184.2% | — | — | — | — | — |
| Net margin | -163.6% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$16.5M | -$12.5M | -$12.5M | -$11.6M | -$27.3M | -$8.9M | -$9.8M | -$10.1M |
| Net income | -$15.4M | -$11.5M | -$11.6M | -$11.0M | -$26.8M | -$8.6M | -$9.4M | -$9.8M |
| Diluted EPS | -$6.61 | -$4.95 | -$11.71 | -$4.70 | -$11.29 | -$3.22 | -$0.44 | -$1.87 |
| Operating cash flow | -$9.8M | -$11.5M | -$7.0M | -$13.0M | -$22.7M | -$6.3M | -$7.6M | -$13.4M |
| Free cash flow | -$10.1M | -$11.6M | -$7.0M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 14, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.